Literature DB >> 22569881

Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.

Timothy Beukelman1, Fenglong Xie, Lang Chen, John W Baddley, Elizabeth Delzell, Carlos G Grijalva, James D Lewis, Rita Ouellet-Hellstrom, Nivedita M Patkar, Kenneth G Saag, Kevin L Winthrop, Jeffrey R Curtis.   

Abstract

OBJECTIVE: To compare the incidence of hospitalized bacterial infections among children with and children without juvenile idiopathic arthritis (JIA) and to examine the effects of selected medications.
METHODS: Using national Medicaid data from 2000 through 2005, we identified a cohort of children with JIA and a comparator cohort of children with attention deficit hyperactivity disorder (ADHD). Exposures to methotrexate (MTX), TNF inhibitors, and oral glucocorticoids (GCs) were determined using pharmacy claims. Patients hospitalized with bacterial infections were identified using coded discharge diagnoses. We calculated adjusted hazard ratios (HR(adj) ) to compare infection incidence rates while adjusting for relevant covariates.
RESULTS: We identified 8,479 JIA patients with 13,003 person-years of followup; 36% took MTX and 16% took TNF inhibitors. Compared with ADHD patients, JIA patients who were not currently taking MTX or TNF inhibitors had an increased rate of infection (HR(adj) 2.0 [95% confidence interval (95% CI) 1.5, 2.5]). Among JIA patients not receiving TNF inhibitor therapy, MTX users had a similar rate of infection as those not currently taking MTX (HR(adj) 1.2 [95% CI 0.9, 1.7]). TNF inhibitor use (irrespective of MTX) resulted in a similar rate of infection as use of MTX without a TNF inhibitor (HR(adj) 1.2 [95% CI 0.8, 1.8]). Use of high-dose GCs (≥10 mg/day of prednisone or equivalent) increased the rate of infection as compared with no GC use, after adjustment for MTX and TNF inhibitor use (HR(adj) 3.1 [95% CI 2.0, 4.7]).
CONCLUSION: Children with JIA had an increased rate of infection compared to children with ADHD. Among children with JIA, the rate of infection was not increased with MTX or TNF inhibitor use, but was significantly increased with high-dose GC use.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22569881      PMCID: PMC3409300          DOI: 10.1002/art.34458

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

2.  Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha.

Authors:  Pamela G Fitch; Randy Q Cron
Journal:  J Rheumatol       Date:  2006-04       Impact factor: 4.666

3.  Abnormalities in the distribution of serum immunoglobulin concentrations in juvenile rheumatoid arthritis.

Authors:  J T Cassidy; R E Petty; D B Sullivan
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

4.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors:  D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal:  N Engl J Med       Date:  2000-03-16       Impact factor: 91.245

5.  Quality of care for patients with rheumatoid arthritis.

Authors:  C H MacLean; R Louie; B Leake; D F McCaffrey; H E Paulus; R H Brook; P G Shekelle
Journal:  JAMA       Date:  2000 Aug 23-30       Impact factor: 56.272

6.  Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis.

Authors:  S Bernatsky; M Hudson; S Suissa
Journal:  Rheumatology (Oxford)       Date:  2007-05-03       Impact factor: 7.580

7.  IgA deficiency in juvenile chronic polyarthritis.

Authors:  D O Barkley; H J Hohermuth; A Howard; D B Webster; B M Ansell
Journal:  J Rheumatol       Date:  1979 Mar-Apr       Impact factor: 4.666

8.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.

Authors:  Michele F Doran; Cynthia S Crowson; Gregory R Pond; W Michael O'Fallon; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2002-09

9.  Predictors of infection in rheumatoid arthritis.

Authors:  Michele F Doran; Cynthia S Crowson; Gregory R Pond; W Michael O'Fallon; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2002-09

10.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

View more
  60 in total

1.  Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid.

Authors:  Linda T Hiraki; Candace H Feldman; Francisco M Marty; Wolfgang C Winkelmayer; Hongshu Guan; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-09-21       Impact factor: 4.794

Review 2.  The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.

Authors:  Melissa A Lerman; C Egla Rabinovich
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

3. 

Authors:  Norbert Wagner; Frauke Assmus; Gabriele Arendt; Erika Baum; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Dirk Föll; Edeltraut Garbe; Jane Hecht; Ulf Müller-Ladner; Tim Niehues; Klaus Überla; Sabine Vygen-Bonnet; Thomas Weinke; Miriam Wiese-Posselt; Michael Wojcinski; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

4.  Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.

Authors:  Ennio Giulio Favalli; Irene Pontikaki; Andrea Becciolini; Martina Biggioggero; Nicola Ughi; Micol Romano; Chiara Crotti; Maurizio Gattinara; Valeria Gerloni; Antonio Marchesoni; Pier Luigi Meroni
Journal:  Clin Rheumatol       Date:  2017-06-08       Impact factor: 2.980

5.  Paediatric rheumatic disease: Biologic therapy and risk of infection in children with JIA.

Authors:  Gerd Horneff
Journal:  Nat Rev Rheumatol       Date:  2012-07-17       Impact factor: 20.543

Review 6.  Biologics in juvenile idiopathic arthritis: a narrative review.

Authors:  Federica Vanoni; Francesca Minoia; Clara Malattia
Journal:  Eur J Pediatr       Date:  2017-07-20       Impact factor: 3.183

Review 7.  Biologic-associated infections in pediatric rheumatology.

Authors:  Gerd Horneff
Journal:  Curr Rheumatol Rep       Date:  2015-11       Impact factor: 4.592

Review 8.  Glucocorticoid treatment in juvenile idiopathic arthritis.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-10-01       Impact factor: 2.631

Review 9.  Infectious complications in juvenile idiopathic arthritis.

Authors:  Andrew Hurd; Timothy Beukelman
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

Review 10.  Diagnosis and management of infectious complications of childhood rheumatic diseases.

Authors:  Rhina D Castillo; Wendy De la Pena; Katherine A B Marzan
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.